GENE ONLINE|News &
Opinion
Blog

Samsung Bioepis
GeneOnline’s Weekly News Highlights: Sept 11-Sept 15
2023-09-19
Samsung Biologics Snaps Up Biogen’s Stake in Samsung Bioepis for $2.3 Billion, Assuming Full Control of Biosimilar Venture
2022-01-28
FDA Approves Samsung Bioepis and Biogen’s Lucentis Biosimilar
2021-09-22
Samsung Bioepis Presents 5-Year Follow-up Results on Trastuzumab Biosimilar at ESMO 2021
2021-09-13
South Korea’s Boryung Launches Avastin Biosimilar Developed by Samsung Bioepis
2021-09-02
Korea Made Humira Biosimilar Begins Sales in Australia, Marks its Presence in Third Overseas Market
2021-03-31
Two South Korean Companies Look to Capture the Biosimilars Market Worth Billions
2020-12-01
Weekly Cover: Acepodia’s NK Cell Therapy Drug Candidate ACE1702 Receives FDA Clearance of IND
2020-01-15
Samsung Bioepis Expects to Earn Profits for the First Time in Eight Years
2019-11-12
Weekly in Asia |Nov
2019-11-12
Weekly in Asia 2019|JUL
2019-08-02
LATEST
International Green Party Showcases AI Solutions for a Healthy and Sustainable Future
2024-09-16
Bio Asia Pacific 2024 Close ASEAN Collaborations: Catalyzing Innovation and Global Partnerships
2024-09-12
Illumina’s IVD Biomarker Test Becomes the First FDA-approved Pan-cancer Companion Diagnostics Kit
2024-09-11
Lotus Pharma Expands in Southeast Asia with Alpha Choay Acquisition from Sanofi
2024-09-06
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void
2024-09-05
EVENT
2024-09-13
ESMO Congress 2024
Barcelona, Spain
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
Scroll to Top